STAT Plus: European regulators could take a harder line on the review of an Agios blood cancer drug
A European regulatory setback for a Bristol-Myers Squibb (BMY) blood-cancer drug could have a negative spillover effect for Agios Pharmaceuticals (AGIO) and its sole wholly owned drug.
On Friday, the European Medicines Agency disclosed that Bristol withdrew a marketing application for Idhifa, a targeted medicine to treat acute myeloid leukemia, after an ongoing review had concluded that the drug’s clinical data did not support approval.
Continue to STAT Plus to read the full story…
